The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Methicillin-Resistant Staphylococcus aureus Therapy: Past, Present, and Future
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) continues to be associated with significant morbidity and mortality. Vancomycin was the "gold standard" of treatment for serious MRSA infections; however, the emergence of less-susceptible strains, poor clinical outcomes, and increased nephrotoxicity with high-dose therapy are challenging its current role as first-line therapy. Linezolid is recommended for PO or IV treatment of skin and skin structure infections (SSSIs) and pneumonia caused by MRSA. Daptomycin (IV) should be considered in patients with MRSA bacteremia and right-sided endocarditis as well as in complicated SSSIs, but should not be used to treat MRSA pneumonia. Tigecycline and telavancin are alternative (IV) treatments for SSSIs caused by MRSA; however, safety concerns have limited use of these agents. Ceftaroline is the newest of the approved parenteral agents for SSSIs caused by MRSA. Several investigational agents with activity against drug-resistant gram-positive pathogens are being developed primarily for treatment of MRSA infections, including tedizolid, dalbavancin, and oritavancin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Wunderink, R. G., Niederman, M. S., Kollef, M. H., Shorr, A. F., Kunkel, M. J., Baruch, A., McGee, W. T., Reisman, A., & Chastre, J. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir895 · Cited by 570
van Hal, S. J., Lodise, T. P., & Paterson, D. L. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir935 · Cited by 512
The 10 × ‘20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020
(2010) · Clinical Infectious Diseases · doi:10.1086/652237 · Cited by 484
Kullar, R., Davis, S. L., Levine, D. P., & Rybak, M. J. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir124 · Cited by 463 · cited 2×
“factor can serve as a predictor of success or failure for vancomycin therapy [17].”
BackgroundThe emerging problem of linezolid-resistant Staphylococcus
Gu, B., Kelesidis, T., Tsiodras, S., Hindler, J., & Humphries, R. M. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks354 · Cited by 332
Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose
Rodvold, K. A., Gotfried, M. H., Cwik, M., Korth-Bradley, J. M., Dukart, G., & Ellis-Grosse, E. J. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl403 · Cited by 304
Self-citationExcess Deaths Associated With Tigecycline After Approval Based on Noninferiority Trials
Prasad, P., Sun, J., Danner, R. L., & Natanson, C. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis270 · Cited by 298
Gould, I. M., David, M. Z., Esposito, S., Garau, J., Lina, G., Mazzei, T., & Peters, G. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.09.028 · Cited by 294
Bhavnani, S. M., Rubino, C. M., Ambrose, P. G., & Drusano, G. L. (2010) · Clinical Infectious Diseases · doi:10.1086/652767 · Cited by 280
Sánchez García, M. (2010) · JAMA · doi:10.1001/jama.2010.757 · Cited by 270
Efficacy and safety of tigecycline: a systematic review and meta-analysis
Yahav, D., Lador, A., Paul, M., & Leibovici, L. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr242 · Cited by 266
Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis
Tasina, E., Haidich, A.-B., Kokkali, S., & Arvanitidou, M. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70177-3 · Cited by 260
The oxazolidinones: past, present, and future
Shaw, K. J., & Barbachyn, M. R. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06330.x · Cited by 259
Vancomycin: We Can't Get There From Here
Patel, N., Pai, M. P., Rodvold, K. A., Lomaestro, B., Drusano, G. L., & Lodise, T. P. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir078 · Cited by 247
Self-citationTelavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens
Rubinstein, E., Lalani, T., Corey, G. R., Kanafani, Z. A., Nannini, E. C., Rocha, M. G., Rahav, G., Niederman, M. S., Kollef, M. H., Shorr, A. F., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq031 · Cited by 246
Moellering, R. C. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr437 · Cited by 236
Holmes, N. E., Turnidge, J. D., Munckhof, W. J., Robinson, J. O., Korman, T. M., O’Sullivan, M. V. N., Anderson, T. L., Roberts, S. A., Gao, W., Christiansen, K. J., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir270 · Cited by 228
Discovering new antimicrobial agents
Moellering, R. C. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.08.018 · Cited by 227
Moore, C. L., Osaki-Kiyan, P., Haque, N. Z., Perri, M. B., Donabedian, S., & Zervos, M. J. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir764 · Cited by 220
Linezolid, the first oxazolidinone antibacterial agent
Leach, K. L., Brickner, S. J., Noe, M. C., & Miller, P. F. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.05962.x · Cited by 195
Cai, Y., Wang, R., Liang, B., Bai, N., & Liu, Y. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01402-10 · Cited by 189
Mohr, J. F., & Murray, B. E. (2007) · Clinical Infectious Diseases · doi:10.1086/518451 · Cited by 185
Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy
Wong-Beringer, A., Joo, J., Tse, E., & Beringer, P. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.10.013 · Cited by 178
Hsu, D. I., Hidayat, L. K., Quist, R., Hindler, J., Karlsson, A., Yusof, A., & Wong-Beringer, A. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.05.007 · Cited by 173
Counterpoint: Vancomycin and Staphylococcus aureus--An Antibiotic Enters Obsolescence
Deresinski, S. (2007) · Clinical Infectious Diseases · doi:10.1086/518452 · Cited by 173
(2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir353 · Cited by 172
Drew, R. H. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.5.775 · Cited by 165
Nguyen, H. M., & Graber, C. J. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp377 · Cited by 132
Moise, P. A., North, D. S., Steenbergen, J. N., & Sakoulas, G. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70200-2 · Cited by 130
A Comparative Review of the Lipoglycopeptides: Oritavancin, Dalbavancin, and Telavancin
Guskey, M. T., & Tsuji, B. T. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.1.80 · Cited by 123
The antibiotic R&D pipeline: an update
Jabes, D. L. (2011) · Current Opinion in Microbiology · doi:10.1016/j.mib.2011.08.002 · Cited by 112
Summary of Ceftaroline Fosamil Clinical Trial Studies and Clinical Safety
File, T. M., Wilcox, M. H., & Stein, G. E. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis559 · Cited by 102
Antibiotics in development targeting protein synthesis
Sutcliffe, J. A. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06323.x · Cited by 96
Talbot, G. H., Powers, J. H., Fleming, T. R., Siuciak, J. A., Bradley, J. S., Boucher, H. W., & on behalf of the CABP-ABSSSI Project Team (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis566 · Cited by 84
Daptomycin: A novel cyclic lipopeptide antimicrobial
Schriever, C. A., Fernández, C., Rodvold, K. A., & Danziger, L. H. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.11.1145 · Cited by 79
Self-citationHigh Vancomycin MIC and Complicated Methicillin-SusceptibleStaphylococcus aureusBacteremia
Aguado, J. M., Juan, R. S., Lalueza, A., Sanz, F., Otero, J. R., Gómez-González, C., & Cháves, F. (2011) · Emerging infectious diseases · doi:10.3201/eid/1706.101037 · Cited by 76
Tigecycline: A Novel Broad-Spectrum Antimicrobial
Slover, C. M., Rodvold, K. A., & Danziger, L. H. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h543 · Cited by 72
Self-citationWalraven, C. J., North, M., Marr-Lyon, L. R., Deming, P., Sakoulas, G., & Mercier, R.-C. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr301 · Cited by 70
Goldberg, E., Paul, M., Talker, O., Samra, Z., Raskin, M., Hazzan, R., Leibovici, L., & Bishara, J. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq179 · Cited by 55
New treatments for methicillin-resistant Staphylococcus aureus
Stryjewski, M. E., & Corey, G. R. (2009) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32832f0a74 · Cited by 50
Campbell, M. L., Marchaim, D., Pogue, J. M., Sunkara, B., Bheemreddy, S., Bathina, P., Pulluru, H., Chugh, N., Wilson, M. N., Moshos, J. A., et al. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r211 · Cited by 45
Vancomycin: A 50-something-yearold antibiotic we still don’t understand
Schilling, A. N., Neuner, E. A., & Rehm, S. J. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.78a.10168 · Cited by 44
Vardakas, K. Z., Mavros, M. N., Roussos, N. S., & Falagas, M. E. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2011.12.011 · Cited by 34
Yang, Y., McBride, M. V., Rodvold, K. A., Tverdek, F. P., Trese, A. M., Hennenfent, J. A., Schiff, G. D., Lambert, B. L., & Schumock, G. T. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090563 · Cited by 13
Self-citation
Cited by
Mechanisms of Methicillin Resistance in Staphylococcus aureus
Peacock, S. J., & Paterson, G. K. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-034516 · Cited by 656
The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection
Mazuski, J. E., Tessier, J. M., May, A. K., Sawyer, R. G., Nadler, E. P., Rosengart, M. R., Chang, P. K., O'Neill, P. J., Mollen, K. P., Huston, J. M., et al. (2017) · Surgical Infections · doi:10.1089/sur.2016.261 · Cited by 573
Linezolid: a review of its properties, function, and use in critical care
Hashemian, S. M., Farhadi, T., & Ganjparvar, M. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s164515 · Cited by 459
Denissen, J., Reyneke, B., Waso-Reyneke, M., Havenga, B., Barnard, T., Khan, S., & Khan, W. (2022) · International Journal of Hygiene and Environmental Health · doi:10.1016/j.ijheh.2022.114006 · Cited by 395
Multidrug-Resistant Bacteria and Alternative Methods to Control Them: An Overview
Vivas, R., Barbosa, A. A. T., Dolabela, S. S., & Jain, S. (2019) · Microbial Drug Resistance · doi:10.1089/mdr.2018.0319 · Cited by 343
Metadata
- Authors
- Rodvold, K. A., & McConeghy, K. W.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-12-16
- Volume
- 58
- Issue
- suppl 1
- Pages
- S20-S27
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2137175695
- Cited by
- 358
- References
- 47
- FWCI
- 21.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.